1-15 of 76
- NEW EPISODE
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
MinuteCE®Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
- NEW EPISODE
The Power of Timing: Therapies That Change Outcomes
MinuteCE®The Power of Timing: Therapies That Change Outcomes
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
- NEW EPISODE
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
MinuteCE®ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
- NEW EPISODE
Precision in Practice—Bringing Targeted Therapy to mHSPC
MinuteCE®Precision in Practice—Bringing Targeted Therapy to mHSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
CME/CEPrecision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Susana Campos, MD, MPH
Robert Coleman, MD, FACOG
Debra Richardson, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
- advertisement
De Novo mHSPC: Recognizing the Patients Who Need More
MinuteCE®De Novo mHSPC: Recognizing the Patients Who Need More
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
ADT Intensification: The Evidence You Can’t Afford to Miss
MinuteCE®ADT Intensification: The Evidence You Can’t Afford to Miss
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Case: Implementing ADT Intensification in mHSPC
MinuteCE®Case: Implementing ADT Intensification in mHSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
MinuteCE®Winning the Battle Against Side Effects: Adverse Event Management in HSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Molecular Profiling in mHSPC: Informing Treatment Selection
MinuteCE®Molecular Profiling in mHSPC: Informing Treatment Selection
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
- advertisement
Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
CME/CEImproving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
Joseph Kim, MD, MPH, MBA, FACHE
Samir Dalia, MD
Christopher Jurief
Ghayas Issa, MD
Amir Fathi, MD
Ghayas Issa, MD
Amir Fathi, MD
